

Special Issue

Targeting the Resistant Tumor Microenvironment in Lymphoma: From Basic Science to Artificial Intelligence

Message from the Guest Editor

Despite recent advances in lymphoma treatment, achieving a durable response remains poor, leading to relapse and resistance to various immunotherapies. Current challenges in reaching a complete response include the high degree of heterogeneity in the tumor microenvironment (TME) composition and the multitude mechanisms through which the TME can counteract the efficacy of therapy. The high pressure exerted by treatments results in the modulation of TME response prompting necessary signals for the development of resistant clones against therapeutic regimens.

Therefore, further research is necessary to explore the complex molecular and cellular ecosystem of lymphoma disease and reveal innovative microenvironmental targets that can reduce the high incidence of relapse and resistance and minimize the development of drug-resistant clones.

This Special Issue welcomes reviews and innovative research articles spanning from basic science to artificial intelligence approaches on the TME-lymphoma crosstalk. The aim is to enhance our understanding of the influence of TME on malignancies and improve therapy effectiveness.

Guest Editor

Dr. Rada Amin

Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA

Deadline for manuscript submissions

closed (31 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/194628

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).